A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured.

Screen time is associated with higher cardiometabolic risk in children and adolescents, according to a study published online.

There is decreased risk for MACE and all-cause mortality in dialysis-dependent patients with ASCVD who are treated with statins.

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with obesity or overweight with weight-related comorbidities.

A higher intake of total potatoes, especially French fries, is associated with an increased risk for type 2 diabetes (T2D).

For adults with hip osteoarthritis and overweight or obesity, a very low-calorie diet (VLCD) plus exercise does not reduce hip pain.

Among patients with PsA, MetS was independently associated with a D2T phenotype, even when accounting for fibromyalgia and disease activity.

The ACLM recommends that physicians advocate for lifestyle interventions as the first-line management for prediabetes and type 2 diabetes.

The table below is a review of notable updates that occurred in July 2025 for investigational products in development.

Women with a history of pregnancy complications may have an increased risk for ischemic stroke at a young age (younger than 50 years).

Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM).

The following are notable drug approvals for July 2025.